July 16, 2026 Arcutis Biotherapeutics Welcomes Chris Peetz to Board of Directors Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors, a strategic decision aimed at driving growth and innovation in immuno-dermatology. Peetz's extensive experience in biopharma leadership positions him as a key asset for the company’s future endeavors.
July 15, 2026 Arcutis Biotherapeutics Prepares for Q2 2026 Financial Results: Conference Call Set for August Arcutis Biotherapeutics will report its Q2 2026 financial results on August 5, followed by a conference call to discuss performance and future strategies. Investors are eager for insights into the company's innovative dermatology solutions and market positioning.
July 08, 2026 FDA Accepts Arcutis’ Application for ZORYVE® Cream to Treat Atopic Dermatitis in Infants The FDA has accepted Arcutis' application to expand ZORYVE® use for treating mild to moderate atopic dermatitis in infants aged 3-24 months. Positive clinical trial data supports its safety and efficacy, making it a promising steroid-free treatment option for young patients. The target action date is February 23, 2027.
July 02, 2026 Arcutis Biotherapeutics Induces Talent with Stock Grants Arcutis Biotherapeutics has granted 61,000 RSUs to nine new employees as part of its strategy to attract top talent. This move supports the company's growth in immuno-dermatology and aligns with its commitment to innovation. The RSUs will vest over four years, fostering employee retention and engagement.
June 30, 2026 Arcutis Biotherapeutics Launches Virtual Health Platform to Improve Access to Dermatology Care Arcutis Biotherapeutics has launched a virtual health platform to enhance access to dermatology for patients with chronic skin diseases. The platform connects patients with certified dermatologists, streamlining the treatment process while ensuring timely care.
June 29, 2026 Arcutis Biotherapeutics Secures FDA Approval for ZORYVE® in Young Children Arcutis Biotherapeutics has received FDA approval for ZORYVE® cream for treating plaque psoriasis in children aged 2 and older. This steroid-free treatment addresses a critical gap, offering safe and effective relief for young patients suffering from this chronic condition.
June 05, 2026 Arcutis Biotherapeutics Induces New Talent with Stock Grants Arcutis Biotherapeutics has awarded 44,000 restricted stock units to six new employees to attract and retain top talent. This initiative reflects the company's commitment to innovation in dermatology and long-term growth. With a structured vesting schedule, Arcutis aims to enhance its workforce and meet patient needs effectively.
June 03, 2026 Arcutis Biotherapeutics Advances Care for Genital Psoriasis with New Expert Guidance Arcutis Biotherapeutics has published new age-specific guidelines for genital psoriasis management, aiming to improve care and reduce stigma. The recommendations emphasize routine assessments and tailored treatment options for different age groups to enhance patient outcomes.
May 26, 2026 Arcutis Biotherapeutics to Showcase Innovations at Goldman Sachs Global Healthcare Conference Arcutis Biotherapeutics will present at the Goldman Sachs Global Healthcare Conference, sharing insights on innovations in immuno-dermatology. Their unique development platform positions them as leaders in addressing inflammatory skin diseases.
May 06, 2026 Arcutis Biotherapeutics, Inc. Reports 2026 Q1 Financial Results: A Strategic Focus Amidst Losses Arcutis Biotherapeutics reported a Q1 2026 net loss of $11.3 million, but revenue rose to $105.3 million, driven by ZORYVE's commercialization. The company is focused on expanding its product offerings and addressing unmet needs in dermatological care despite challenging financial conditions.
May 06, 2026 Arcutis Biotherapeutics Reports Strong Q1 2026 Financial Results and Business Developments Arcutis Biotherapeutics reported a strong Q1 2026 with $105.4 million in product sales, driven by the demand for ZORYVE. The company also made significant advancements in clinical trials and expanded its sales force, positioning itself for continued growth in immuno-dermatology.
April 27, 2026 Arcutis Biotherapeutics Submits Supplemental New Drug Application for ZORYVE® Cream Arcutis Biotherapeutics has submitted an sNDA to the FDA to expand ZORYVE cream's indication to treat atopic dermatitis in infants as young as three months. Backed by clinical trials, this submission aims to address the critical need for effective, safe treatments for pediatric eczema.
April 22, 2026 Arcutis Biotherapeutics Achieves Landmark Recommendation for ZORYVE in Pediatric Atopic Dermatitis Arcutis Biotherapeutics' ZORYVE cream has received a strong recommendation from the AAD for treating pediatric atopic dermatitis. Highlighting efficacy and safety, the cream is now a pivotal option for children suffering from this skin condition. This endorsement signifies a major advancement in pediatric dermatology.
April 15, 2026 Arcutis Biotherapeutics Set to Announce Q1 2026 Financial Results Arcutis Biotherapeutics will release its Q1 2026 financial results on May 6, followed by a conference call to discuss performance and strategy. Investors are eager for insights into the company's growth and pipeline of dermatology treatments.
March 31, 2026 Arcutis Biotherapeutics to Present at Needham Virtual Healthcare Conference Arcutis Biotherapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. The company will host a Fireside Chat to discuss its innovative dermatological therapies, reflecting its commitment to addressing critical patient needs.
March 28, 2026 Arcutis Biotherapeutics Unveils Promising Phase 2 Results for ZORYVE in Infants with Atopic Dermatitis Arcutis Biotherapeutics revealed promising Phase 2 trial results for ZORYVE cream in treating atopic dermatitis in infants. The study showed significant symptom relief and a strong safety profile, prompting plans for FDA submission to expand treatment options for young patients.
March 18, 2026 Arcutis Biotherapeutics Unveils New Clinical Data at 2026 AAD Annual Meeting Arcutis Biotherapeutics will present significant new clinical data at the AAD 2026 Annual Meeting, including findings from the INTEGUMENT-INFANT Phase 2 trial for atopic dermatitis in infants. The company aims to expand treatment options for pediatric patients suffering from skin conditions.
March 10, 2026 Arcutis Biotherapeutics Publishes Positive Long-Term Data for ZORYVE® in Young Children with Atopic Dermatitis Arcutis Biotherapeutics has published encouraging long-term data for ZORYVE® cream in children aged 2-5 with atopic dermatitis. The study shows a strong safety profile and significant efficacy, marking a breakthrough in pediatric dermatology.
March 05, 2026 Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer Arcutis Biotherapeutics has promoted Mas Matsuda to Executive Vice President and Chief Legal Officer to strengthen its legal and compliance framework. Matsuda, who previously secured six FDA approvals for ZORYVE, will guide the company through its next growth phase. His expertise is crucial as Arcutis expands its dermatology market presence.
March 03, 2026 Arcutis Biotherapeutics Commences Clinical Trials for Innovative Atopic Dermatitis Treatment Arcutis Biotherapeutics has initiated a Phase 1a/1b clinical trial for ARQ-234, a new treatment aimed at managing atopic dermatitis by regulating immune responses. The study will assess safety and efficacy in both healthy volunteers and patients, highlighting Arcutis' commitment to innovation in dermatological care.
February 27, 2026 Arcutis Biotherapeutics Set to Showcase Innovations at TD Cowen Health Care Conference Arcutis Biotherapeutics will showcase its advancements in immuno-dermatology at the TD Cowen Health Care Conference from March 2-4, 2026. The company focuses on innovative therapies for inflammatory skin diseases and aims to engage stakeholders with updates on its product pipeline and strategic direction.
February 25, 2026 Arcutis Biotherapeutics Reports Strong Financial Performance in 2025 Arcutis Biotherapeutics achieved a remarkable 90% year-over-year revenue growth in 2025, fueled by the successful launch of ZORYVE. The company anticipates continued growth with expanded market access and innovative product developments on the horizon.
February 25, 2026 Arcutis Biotherapeutics, Inc. Reports Strong Progress in 2025 Annual Financial Results Arcutis Biotherapeutics, Inc. reports strong revenue growth in 2025, reaching $376 million, primarily due to the success of ZORYVE products. Despite financial losses, the company is optimistic about its strategic initiatives and product pipeline aimed at addressing dermatological needs.
February 24, 2026 Arcutis Biotherapeutics Welcomes Max Homa to 'Free to Be Me' Campaign for Seborrheic Dermatitis Awareness Max Homa has joined Arcutis Biotherapeutics' 'Free to Be Me' campaign to raise awareness for seborrheic dermatitis. Sharing his personal journey, Homa emphasizes the importance of proper diagnosis and effective treatment using ZORYVE, a breakthrough topical foam that has shown promising clinical results.
February 05, 2026 Arcutis Biotherapeutics Announces Inducement Grants for New Employees Arcutis Biotherapeutics has announced inducement grants of 94,000 RSUs to 12 new hires, aiming to attract top talent in immuno-dermatology. This strategic move enhances the company’s potential for innovation and growth in the competitive biopharmaceutical sector.
February 02, 2026 Arcutis Biotherapeutics Reports Promising Phase 2 Trial Results for ZORYVE® in Infants Arcutis Biotherapeutics has reported encouraging Phase 2 trial results for ZORYVE® cream, showing significant efficacy in treating atopic dermatitis in infants. The study revealed that 58% of participants experienced a notable reduction in disease severity, highlighting the cream's safety and therapeutic potential for young patients.
January 26, 2026 Arcutis Biotherapeutics Terminates Promotion Agreement with Kowa: A New Era for ZORYVE Arcutis Biotherapeutics has ended its promotion agreement with Kowa, allowing it to directly market ZORYVE for inflammatory skin conditions. This strategic move aims to enhance ZORYVE's adoption in primary care and dermatology, with further details expected in the upcoming earnings call.
January 22, 2026 Arcutis Biotherapeutics Announces Upcoming Financial Results and Investor Conference Participation Arcutis Biotherapeutics will report its Q4 and full-year 2025 financial results on February 25, 2026, and participate in the Guggenheim Biotech Summit. These events will provide key insights into the company's performance and strategic direction in immuno-dermatology.
January 21, 2026 Arcutis Biotherapeutics Unveils Nationwide Survey Highlighting Concerns Over Topical Steroids and the Need for Long-Term Treatment Strategies A nationwide survey by Arcutis Biotherapeutics reveals that many Americans with chronic inflammatory skin conditions still rely on reactive treatment plans. The findings underscore concerns over the long-term use of topical steroids and emphasize the need for innovative, proactive management strategies.
January 12, 2026 Arcutis Biotherapeutics Sets Strategic Priorities for 2026 Arcutis Biotherapeutics outlines its strategic priorities for 2026, aiming to expand ZORYVE's market presence and advance its innovative pipeline. The company plans to increase sales, enhance its dermatology sales force, and explore new therapeutic areas.
December 08, 2025 Arcutis Biotherapeutics Welcomes Amit Munshi to Board of Directors, Celebrates Bhaskar Chaudhuri's Retirement Arcutis Biotherapeutics announces the appointment of Amit Munshi to its Board of Directors, marking a new chapter for the company. The retirement of founder Bhaskar Chaudhuri highlights his significant contributions to Arcutis's growth and success.
November 17, 2025 Arcutis Biotherapeutics Secures FDA Acceptance for ZORYVE® Cream to Treat Plaque Psoriasis in Young Children Arcutis Biotherapeutics has received FDA acceptance for ZORYVE® cream to treat plaque psoriasis in children as young as two. This potential approval would provide a much-needed treatment option for managing this chronic skin condition in young patients.
November 13, 2025 Arcutis Biotherapeutics Completes Enrollment in Pivotal Pediatric Study for ZORYVE® Cream Arcutis Biotherapeutics has successfully completed enrollment for its Phase 2 INTEGUMENT-INFANT study assessing ZORYVE cream in infants with atopic dermatitis. With 101 participants, the study aims to evaluate this innovative treatment option and address the urgent need for alternatives to traditional therapies.
November 07, 2025 Arcutis Biotherapeutics Announces Inducement Grants for New Employees Arcutis Biotherapeutics announced the grant of 51,000 RSUs to new employees, reflecting its strategic focus on talent retention and innovation in dermatology. This move aims to align employee interests with company growth and strengthen its competitive position in the biopharmaceutical sector.
November 04, 2025 Arcutis Biotherapeutics Publishes Promising Long-Term Data for ZORYVE® in Seborrheic Dermatitis Arcutis Biotherapeutics has released long-term data showing ZORYVE® foam's effectiveness for seborrheic dermatitis over 52 weeks. The study indicates high tolerability and significant improvements in symptoms, marking a significant advancement in dermatological treatments.
October 30, 2025 Tori Spelling and Stella McDermott Join Forces with Arcutis Biotherapeutics for the *Free to Be Me* Campaign The *Free to Be Me* campaign, led by Tori Spelling and her daughter Stella, aims to raise awareness about inflammatory skin conditions. It highlights personal stories and promotes effective treatments like ZORYVE for better skin health.
October 30, 2025 Arcutis Biotherapeutics Launches ZORYVE® Cream for Young Children with Atopic Dermatitis Arcutis Biotherapeutics has launched ZORYVE® cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2 to 5. This once-daily, steroid-free treatment aims to provide long-term relief and is supported by patient assistance programs.
October 28, 2025 Arcutis Biotherapeutics Outlines Growth Strategy and Reports Strong Q3 2025 Results Arcutis Biotherapeutics showcased strong financial performance in Q3 2025, with a significant revenue increase driven by ZORYVE products. The company outlined growth strategies aimed at expanding its market share and enhancing its product pipeline.
October 28, 2025 Arcutis Biotherapeutics, Inc. Reports Promising Q3 2025 Financial Results Amid Product Expansion Arcutis Biotherapeutics announced significant revenue growth in Q3 2025, reporting $99.21 million, primarily due to sales of ZORYVE. The company faces ongoing financial challenges but is expanding its product offerings and market reach.
October 27, 2025 Arcutis Biotherapeutics to Showcase Innovations at Upcoming Investor Conferences Arcutis Biotherapeutics will participate in two key investor conferences in November 2025, aiming to engage with the investment community about their innovative dermatological therapies. Their commitment to addressing immune-mediated skin conditions is highlighted through this strategic outreach.
October 24, 2025 Arcutis Biotherapeutics Highlights Promising Data for ZORYVE® at Fall Clinical Dermatology Conference Arcutis Biotherapeutics presented new data at the Fall Clinical Dermatology Conference showing that ZORYVE® cream significantly improves sleep and reduces symptoms of atopic dermatitis. The findings underscore its long-term efficacy and tolerability, making it a leading treatment option for patients of all ages.
October 06, 2025 FDA Approves Arcutis’ ZORYVE® Cream for Young Children with Atopic Dermatitis The FDA has approved ZORYVE® cream for children aged 2 to 5 with mild to moderate atopic dermatitis, providing a much-needed treatment alternative to steroids. Clinical trials showed significant improvements in eczema symptoms, highlighting its efficacy and safety. Arcutis is committed to ensuring patient access through various support programs.
October 03, 2025 Arcutis Biotherapeutics Announces Inducement Grants as Part of Growth Strategy Arcutis Biotherapeutics has granted 94,500 RSUs to 12 new employees to attract top talent in immuno-dermatology. This strategic move aims to align employee incentives with the company's long-term success and innovation in dermatological treatments.
September 29, 2025 Arcutis Biotherapeutics Prepares for Investor Day and Q3 2025 Financial Results Arcutis Biotherapeutics is set to report Q3 financial results on October 28, 2025, alongside a virtual Investor Day. The event will highlight the growth strategy for ZORYVE, clinical developments, and financial forecasts, providing valuable insights for investors.
August 06, 2025 Arcutis Biotherapeutics, Inc. Reports Q2 2025 Financial Results: A Step Forward in Dermatological Innovations Arcutis Biotherapeutics reports significant revenue growth in Q2 2025, driven by strong sales of its flagship product, ZORYVE. The company has expanded its product approvals and entered strategic partnerships while managing ongoing operational challenges.
May 06, 2025 Arcutis Biotherapeutics, Inc. Reports Q1 2025 Financial Results: Progress Amidst Challenges Arcutis Biotherapeutics reported a Q1 2025 net loss of $25.1 million with significant revenue growth driven by ZORYVE sales. The company is advancing its product pipeline while managing costs and exploring strategic partnerships.
April 02, 2025 Arcutis Biotherapeutics and Padagis Agree to Stay Patent Litigation Arcutis Biotherapeutics and Padagis have agreed to pause their patent litigation, allowing Arcutis to maintain exclusivity over ZORYVE, its psoriasis treatment. The agreement also extends the Hatch-Waxman stay, enabling Arcutis to further solidify its strategic position in the biopharmaceutical market.
March 27, 2025 Arcutis Biotherapeutics to Showcase Innovations at the 24th Annual Needham Virtual Healthcare Conference Arcutis Biotherapeutics will showcase its advancements in immuno-dermatology at the Needham Virtual Healthcare Conference from April 7-10, 2025. The company will hold a Fireside Chat on April 8 to discuss strategic initiatives and its robust product pipeline.
March 07, 2025 Arcutis Biotherapeutics Showcases Promising Data on ZORYVE at AAD 2025 Arcutis Biotherapeutics unveiled promising data on ZORYVE at the AAD 2025, showcasing its efficacy and safety for treating atopic dermatitis and psoriasis. The results highlight ZORYVE's potential as a preferred alternative to traditional therapies, with ongoing regulatory reviews expected to enhance its availability.
March 05, 2025 Arcutis Biotherapeutics Grants Restricted Stock Units to New Employees Arcutis Biotherapeutics has awarded 27,000 restricted stock units to three new employees to attract top talent in the biopharmaceutical sector. This move, approved by the Board, aligns with Nasdaq regulations and aims to enhance long-term commitment and performance in developing innovative dermatological therapies.
February 28, 2025 Arcutis Biotherapeutics Set to Showcase Key Research at AAD Annual Meeting Arcutis Biotherapeutics will showcase vital research on atopic dermatitis and psoriasis at the AAD Annual Meeting 2025. Key presentations include safety data for roflumilast cream and improvements from the ARRECTOR trial. The company also emphasizes culturally conscious dermatology initiatives.
February 26, 2025 FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® in Young Children The FDA has accepted Arcutis' supplemental New Drug Application for ZORYVE cream, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5. With promising clinical trial results, this treatment could significantly improve the quality of life for young patients suffering from eczema.
February 25, 2025 Arcutis Biotherapeutics, Inc. Releases 2024 Annual Report: Growth Amidst Challenges Arcutis Biotherapeutics' 2024 annual report reveals significant revenue growth to $196.5 million, driven by ZORYVE product expansions. Despite operational challenges and net losses of $140 million, the company remains optimistic about future prospects and market presence.
February 25, 2025 Arcutis Biotherapeutics Reports Impressive Financial Results for Q4 and Full Year 2024 Arcutis Biotherapeutics reported strong financial results for Q4 and full-year 2024, driven by a 471% increase in revenue from its flagship product, ZORYVE. The company is expanding its product line and maintaining a robust pipeline while demonstrating strategic financial management.
February 24, 2025 Arcutis Biotherapeutics Reports Positive Findings from INTEGUMENT-PED Trial for ZORYVE in Young Children Arcutis Biotherapeutics has published promising results from the INTEGUMENT-PED trial, showcasing ZORYVE cream's effectiveness in treating atopic dermatitis in children aged 2-5. The study demonstrated significant improvements in various efficacy endpoints, leading to hopes for FDA approval.
February 18, 2025 Arcutis Biotherapeutics to Showcase Innovations at TD Cowen Annual Health Care Conference Arcutis Biotherapeutics will participate in the TD Cowen Annual Health Care Conference, highlighting its advancements in immuno-dermatology. The company aims to engage with investors while showcasing its innovative therapeutic pipeline aimed at treating immune-mediated skin conditions.
February 16, 2025 SWOT Analysis of Arcutis Biotherapeutics, Inc. in 2025 This SWOT analysis of Arcutis Biotherapeutics, Inc. as of 2025 examines its strengths, including an innovative product portfolio, alongside weaknesses like financial instability. It highlights opportunities for growth in dermatological markets and threats from competition and market volatility.
February 05, 2025 Arcutis Biotherapeutics Announces Inducement Grants for New Employees Arcutis Biotherapeutics has granted 62,000 restricted stock units (RSUs) to eight new employees as part of its strategy to attract talent in the biopharmaceutical sector. This move supports their commitment to innovation in immuno-dermatology and follows Nasdaq guidelines for inducement awards.
November 06, 2024 Arcutis Biotherapeutics, Inc. Reports Promising Growth in Q3 2024 Financial Results Arcutis Biotherapeutics reported strong revenue growth in Q3 2024, driven by its ZORYVE product line. Despite significant net losses, the company is expanding its product offerings to meet dermatological needs, positioning itself for future success.
August 14, 2024 Arcutis Biotherapeutics Reports Q2 2024 Financial Results: A Mixed Bag of Growth and Challenges Arcutis Biotherapeutics reported significant revenue growth in Q2 2024, particularly from its ZORYVE product, while facing operational losses and rising expenses. The company is strategically managing its finances to navigate future challenges in the dermatology market.
May 14, 2024 Arcutis Biotherapeutics, Inc. Reports Strong Q1 2024 Performance Arcutis Biotherapeutics, Inc. announced impressive Q1 2024 results, with a revenue increase to $12.2 million thanks to the ZORYVE foam launch. The company continues to strengthen its financial position while focusing on innovative dermatological solutions.
